1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Evidence for AI in Health (EVAH) initiative is sponsored by Wellcome Trust, Gates Foundation, Novo Nordisk Foundation. This initiative supports the evaluation of AI tools for health in low- and middle-income countries. It aims to generate robust, locally-led evidence on the use of AI-enabled clinical decision support tools (CDSTs) in primary and community healthcare settings.
Get alerted about grants like this
Save a search for “Wellcome Trust, Gates Foundation, Novo Nordisk Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Evidence for AI in Health (EVAH) RFP | The Abdul Latif Jameel Poverty Action Lab Evidence for AI in Health (EVAH) RFP The Evidence for AI in Health (EVAH) initiative is supported by the Wellcome Trust , Gates Foundation , and Novo Nordisk Foundation , and delivered in partnership with the Abdul Latif Jameel Poverty Action Lab (J-PAL) and the African Population and Health Research Center (APHRC).
EVAH’s first request for proposals (RFP) supports locally-led evaluations of AI-enabled clinical decision support tools (CDSTs) that are ready for real-world use and designed to assist frontline workers with clinical tasks—such as triage, diagnosis, or referral—within primary and community health care settings in Sub-Saharan Africa, South Asia, and Southeast Asia.
The Evidence for AI in Health (EVAH) initiative Spring 2026 RFP is now closed. Below are the key dates: RFP opens: February 20, 2026 RFP questions accepted: Questions must have been submitted to [email protected] by March 6, 2026 to be published and answered in the FAQ below. Due to the volume of questions and to ensure applicants have equal access to information, we are unable to respond individually to every inquiry.
Proposals due: (CLOSED) April 1, 2026 at 10:00am EDT / 4:00pm Central Africa Time / 7:30pm Indian Standard Time Anticipated notification date: June 2026 Note: This is when we estimate that applicants will first be notified whether their proposal is advancing with a funder (either Wellcome Trust, Gates Foundation, or Novo Nordisk Foundation) for further due diligence.
Final funding decisions and associated timeline to award remain subject to each funder’s internal due diligence processes. Researchers may apply for one of the following funding pathways: Pathway A: supports real-world evaluation of AI-enabled CDSTs that are early in deployment.
The pathway focuses on how the tools perform in practice, including usability, workflow integration, adoption, and safety, and supports research that can inform future impact evaluations. (Up to USD $1,000,000) Pathway B : supports rigorous impact evaluations of AI-enabled CDSTs that are ready to be deployed at scale. This pathway focuses on measuring the effects of these tools on health outcomes and system performance at scale.
(Up to USD $3,000,000) This call is intended for organizations or consortia that have access to an AI-enabled CDST already deployed or ready for deployment in primary health care settings, and the capacity to conduct—or partner with institutions that can conduct—rigorous evaluations.
Applicants may include nonprofit organizations, for-profit companies, international organizations, government agencies, academic institutions, or collaborations among these actors.
Proposals should be led by institutions based in the regions of focus and designed to generate decision-relevant evidence for Ministries of Health, implementers, and funders on how AI-enabled CDSTs can be responsibly integrated into primary health care systems and, where appropriate, inform future scale-up decisions. Please refer to the RFP overview for additional details on eligibility and priorities.
For EVAH RFPs, please follow the directions listed below: When you are ready to apply, please refer to these instructions to create your team’s profile on Wizehive, our application portal. Please note that we are adapting WizeHive’s “Organization Profile” feature to serve as a “Proposal Team Profile. ” As such, each team profile corresponds to a single proposal.
Teams will now be able to collaborate on their proposal in WizeHive. Submit your proposal by April 1, 2026 at 10:00am Eastern Daylight Time (4:00pm Central Africa Time; 7:30pm Indian Standard Time). Please see the application guidelines at the bottom of this page for a preview of application questions and required materials.
The application guidelines include a checklist of required materials and guidance on what to address within each narrative prompt of the application. We recommend reading the Application Guidelines document in detail before answering the proposal questions in WizeHive . Questions on RFP priorities, application and review processes, eligibility, and general inquiries were collected through [email protected] until March 6 .
Questions and responses are anonymized and published below under Frequently Asked Questions . Due to the volume of questions and to ensure applicants have equal access to information, we are unable to respond individually to every inquiry. Technical support for WizeHive, the application platform, will be provided throughout the RFP process.
Please see the RFP Overview below for more information. Below, please find (1) an RFP Overview; (2) Application Guidelines, which includes a preview of the application questions you will complete on the WizeHive portal; and (3) budget template. Please use the budget template to structure your proposal budget.
All application materials should be completed in or uploaded to our online portal, WizeHive —only applications submitted there can be considered. Request for Proposals Overview EVAH Application Guidelines Frequently Asked Questions WizeHive Application Instructions WizeHive Application Instructions
Key questions and narrative sections extracted from the solicitation.
Describe the AI-enabled Clinical Decision Support Tool (CDST) to be evaluated
Describe the evaluation design and methodology
Describe team capacity to conduct rigorous evaluations
Scoring criteria used to review proposals for this grant.
Based on current listing details, eligibility includes: Applications are invited from a wide range of institutions, including non-profits, companies, academic institutions and government agencies. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.